B-cell lymphoma+1
Not recruitingStudy on the Safety and Effects of Englumafusp Alfa with Obinutuzumab and Glofitamab for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Study on the Safety and Effects of Englumafusp Alfa with Obinutuzumab and Glofitamab for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Disease:B-cell lymphomaB-cell lymphoma refractory
- Substances:Englumafusp AlfaGlofitamab+2
France- Participants:18–64 years · 65+ years
- Substances:Englumafusp Alfa
- Sponsor:F. Hoffmann-La Roche AG











